ATE373483T1 - Zusammensetzung zur behandlung von prostatakrebs - Google Patents

Zusammensetzung zur behandlung von prostatakrebs

Info

Publication number
ATE373483T1
ATE373483T1 AT00989699T AT00989699T ATE373483T1 AT E373483 T1 ATE373483 T1 AT E373483T1 AT 00989699 T AT00989699 T AT 00989699T AT 00989699 T AT00989699 T AT 00989699T AT E373483 T1 ATE373483 T1 AT E373483T1
Authority
AT
Austria
Prior art keywords
prostate cancer
composition
treating prostate
living mammal
glycosidase
Prior art date
Application number
AT00989699T
Other languages
English (en)
Inventor
Muharrem Gokcen
Original Assignee
Immunolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunolytics Inc filed Critical Immunolytics Inc
Application granted granted Critical
Publication of ATE373483T1 publication Critical patent/ATE373483T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00989699T 1999-10-28 2000-10-25 Zusammensetzung zur behandlung von prostatakrebs ATE373483T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/428,375 US6428785B1 (en) 1999-10-28 1999-10-28 Method and composition for treating prostate cancer

Publications (1)

Publication Number Publication Date
ATE373483T1 true ATE373483T1 (de) 2007-10-15

Family

ID=23698630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00989699T ATE373483T1 (de) 1999-10-28 2000-10-25 Zusammensetzung zur behandlung von prostatakrebs

Country Status (9)

Country Link
US (2) US6428785B1 (de)
EP (1) EP1242110B1 (de)
JP (1) JP2003513931A (de)
CN (1) CN1176714C (de)
AT (1) ATE373483T1 (de)
AU (1) AU2617901A (de)
CA (1) CA2389176A1 (de)
DE (1) DE60036490T2 (de)
WO (1) WO2001034176A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595199B1 (en) * 1998-07-31 2009-09-29 Max-Planck-Gesellschaft zur Förderung der Wissenchaften e.V. Method of detecting amyloid-like fibrils or protein aggregates
ES2424348T3 (es) * 2002-06-24 2013-10-01 Incept, Llc Cargas y métodos para desplazar tejidos para mejorar los resultados radiológicos
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
AU2003298972A1 (en) * 2003-07-14 2005-02-04 Dmitry Dmitrievich Genkin Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US7354740B2 (en) 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
GB2408207A (en) * 2003-11-24 2005-05-25 Johnson & Johnson Medical Ltd Wound dressing for the controlled release of therapeutic agents comprising also an inhibitor of a protease enzyme & a linker group cleavable by such an enzyme
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
EP1718759A1 (de) * 2004-02-19 2006-11-08 Bayer HealthCare AG Diagnostika und therapeutika für mit kallikrein 3 (klk3) assoziierte krankheiten
CA2555356C (en) * 2004-04-09 2015-06-16 Nicholas Piramal India Limited Herbal extract for renal disorders
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
EP1880733A4 (de) * 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Verfahren zur verlängerung der lebensdauer eines menschen und von tieren
CN101374941A (zh) * 2005-12-29 2009-02-25 人类起源公司 采集和保存胎盘干细胞的改良组合物及其使用方法
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
EP2049151A4 (de) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Verfahren und zusammensetzungen zur behandlung von krebs
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
JP5372769B2 (ja) * 2006-11-28 2013-12-18 シーエルエス セラピューティック リミティド 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
JP2010519211A (ja) 2007-02-15 2010-06-03 アラーガン、インコーポレイテッド 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用
CN101313926B (zh) * 2007-05-30 2012-12-26 中央研究院 转录调控物组合物
EP3858347A3 (de) 2007-08-17 2021-12-01 Purdue Research Foundation Psma-bindungsliganden-linker-konjugate und anwendungsverfahren
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
AU2009283161A1 (en) 2008-08-22 2010-02-25 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2334695B1 (de) 2008-10-01 2015-12-23 Quintessence Biosciences, Inc. Therapeutische ribonukleasen
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CA3042067C (en) 2009-12-15 2022-10-18 Incept, Llc Implants and biodegradable fiducial markers
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2011127113A1 (en) 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2012006634A2 (en) * 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CN113559126A (zh) 2011-06-01 2021-10-29 人类起源公司 利用胎盘干细胞治疗疼痛
WO2013091657A1 (en) * 2011-12-22 2013-06-27 Herlev Hospital Therapeutic applications of calcium electroporation to effectively induce tumor necrosis
IN2015KN00596A (de) 2012-08-10 2015-07-17 Osio Corp D B A Yolia Health
MX2015006109A (es) 2012-11-15 2016-02-05 Endocyte Inc Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
RS65324B1 (sr) 2013-10-18 2024-04-30 Novartis Ag Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
CZ307195B6 (cs) 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
US10183064B2 (en) * 2014-03-20 2019-01-22 Technion Research & Development Foundation Limited Delivery system comprising a proteolytic enzyme or effector thereof for use in a method for oral treatment and uses thereof
US10064681B2 (en) 2014-04-03 2018-09-04 Corbin Clinical Resources, Llc Method, system, and device for planning and performing, guided and free-handed transperineal prostate biopsies
US10743909B2 (en) 2014-04-03 2020-08-18 Corbin Clinical Resources, Llc Transperineal prostate biopsy device, systems, and methods of use
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
GB2528304B (en) * 2014-07-17 2020-05-13 Cambridge Univ Hospitals Nhs Foundation Trust Perineal prostate biopsy apparatus
US20170266123A1 (en) * 2014-08-14 2017-09-21 Dana-Farber Cancer Institute, Inc. Coated particles for drug delivery
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
WO2017074257A1 (en) * 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
CN105255825B (zh) * 2015-11-16 2019-07-19 广州赛莱拉干细胞科技股份有限公司 一种跟腱来源肌腱干细胞原代分离消化液及分离方法
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
EP3743048A4 (de) 2018-01-23 2021-09-29 Technion Research & Development Foundation Limited Kollagenase-beladene liposomen zur verbesserung der arzneimittelabgabe
EP3698806A1 (de) * 2019-02-19 2020-08-26 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Chemisches skalpell
CN111705051A (zh) * 2020-07-28 2020-09-25 金紫晶(南京)生物医药技术有限公司 一种复合消化酶及复合消化酶冻干粉
CN112941009B (zh) * 2021-02-22 2024-03-01 新格元(南京)生物科技有限公司 一种ffpe样本预处理液及从ffpe样本中分离单细胞的方法
CN115671267A (zh) * 2021-07-23 2023-02-03 上海宝济药业有限公司 一种皮下抗生素药物组合物
CN117258047B (zh) * 2023-10-12 2024-06-18 成都世联康健生物科技有限公司 一种猪牙髓组织脱细胞外基质水凝胶及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4678668A (en) 1985-10-28 1987-07-07 Md Associates Method of reducing soft tissue swelling and pain
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
AU5045690A (en) * 1989-01-27 1990-08-24 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
US5116615A (en) 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5051257A (en) 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5958406A (en) * 1994-11-22 1999-09-28 Phairson Medical Inc. Acne treatment with multifunctional enzyme
US5422261A (en) 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
CA2176934A1 (en) 1993-11-17 1995-05-26 Ramnath Sasisekharan Method for inhibiting angiogenesis using heparinase
WO1996000283A1 (en) 1994-06-24 1996-01-04 Boehringer Mannheim Corporation A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5658730A (en) 1994-12-23 1997-08-19 Ctrc Research Foundation Methods of human prostate cancer diagnosis
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
AU7130696A (en) 1995-09-19 1997-04-09 Schering Aktiengesellschaft Combination of beta-interferon for the treatment of prostate cancer
US5783182A (en) 1996-01-30 1998-07-21 Baylor College Of Medicine Method for identifying metastatic sequences
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US5989888A (en) 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
US5716541A (en) 1996-09-23 1998-02-10 Bayer Corporation Azeotrope-like compositions of 1,1,1,3,3 pentafluoropropane and tetramethylsilane
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease

Also Published As

Publication number Publication date
CN1384754A (zh) 2002-12-11
DE60036490T2 (de) 2008-06-19
DE60036490D1 (de) 2007-10-31
EP1242110B1 (de) 2007-09-19
AU2617901A (en) 2001-06-06
US20020061300A1 (en) 2002-05-23
WO2001034176A1 (en) 2001-05-17
EP1242110A1 (de) 2002-09-25
JP2003513931A (ja) 2003-04-15
US6428785B1 (en) 2002-08-06
CA2389176A1 (en) 2001-05-17
US6913744B2 (en) 2005-07-05
CN1176714C (zh) 2004-11-24
US20020106359A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
ATE373483T1 (de) Zusammensetzung zur behandlung von prostatakrebs
ATE255418T1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
MEP26808A (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
PL350042A1 (en) Serine protease inhibitors
ATE543509T1 (de) Material und verfahren zur förderung der reparatur von nervengewebe
ATE518540T1 (de) Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
DE60042153D1 (de) Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
DE60139078D1 (de) Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser-sehkraftkorrektur-chirurgie
ATE121946T1 (de) Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
ATE255904T1 (de) Fibrin-/fibrinogen-abbau und gerinsel-auflösung durch eine fibrinolytische matrix- metallproteinase
ATE277943T1 (de) Trypsininhibitoren
ATE461707T1 (de) Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE493147T1 (de) Pharmazeutische zusammensetzungen und methoden nützlich zur behandlung von krebs oder leberfibrose
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
EP1060747A3 (de) Fibrin-(fibrinogen-) Abbau und Gerinsel-Auflösung durch eine fibrinolytische Metallproteinase
ATE290878T1 (de) Inhibierung von invasiver remodulierung
DE60225939D1 (de) Aspirin enthaltende transdermale pharmazeutische zusammensetzung zur behandlung von verkalkung
NZ331374A (en) Phenanthridine compounds and pharmaceutical compositions thereof
FR2812549B1 (fr) Associations dalfopristine/quinupristine avec le cefpirome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties